Secondary Polycythemia in Hepatocellular Carcinoma: Treat or No Treat

Poernomo Budi Setiawan(1), Ummi Maimunah(2), Nenci Siagian(3),


(1) Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine Universitas Airlangga/Dr Soetomo General Hospital, Surabaya
(2) Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine Universitas Airlangga/Dr Soetomo General Hospital, Surabaya
(3) Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine Universitas Airlangga/Dr Soetomo General Hospital, Surabaya
Corresponding Author

Abstract


A 45-year man with a chronic hepatitis B virus (HBV) infection, elevated alphafetoprotein (AFP) 628ng/dL and Abdominal CT-scan features of Hepatocellular Carcinoma was admitted with polycythemia condition (haemoglobin 20.4g/dL, haematocrit 65.4%). Elevated of erythropoietin (EPO) serum level confirmed the polycythemia was because of hepatocellular carcinoma (HCC) as a paraneoplastic syndrome. Based on diganosis criteria of HCC by Indonesian Association for the Study of the Liver 2017, the patient was diagnosed with HCC Barcelona clinic liver cancer (BCLC) B and was treated with trans arterial chemotherapy and embolization (TACE) with mixed doxorubicin. Aspirin 80mg once daily was given to patient to prevent thrombosis event. One month later after TACE, haemoglobin and haematocrite didn’t improve. Then 4 months later the patient died of cardiovascular event in the last admission at district hospital.


Keywords


hepatocellular carcinoma (HCC); polycythemial; trans arterial chemotherapy and embolization (TACE)

Full Text: PDF

Article Metrics

Abstract View : 380 times
PDF Download : 382 times

DOI: 10.24871/211202064-67

Refbacks

  • There are currently no refbacks.